Register
Forgot your password?

Biomarkers and transthoracic echocardiography for heart failure with preserved ejection fraction early detection

Authors: Dzhioeva O.N., Ivanova A.A., Rogozhkina E.A., Timofeev Yu.S., Drapkina O.M.

Company: National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2026-20-2-167-174

For citation: Dzhioeva O.N., Ivanova A.A., Rogozhkina E.A., Timofeev Yu.S., Drapkina O.M. Biomarkers and transthoracic echocardiography for heart failure with preserved ejection fraction early detection. Creative Cardiology. 2026; 20 (2): 167–174 (in Russ.). DOI: 10.24022/1997-3187-2026-20-2-167-174

Received / Accepted:  07.05.2026 / 21.05.2026

Keywords: heart failure with preserved ejection fraction early identification circulating biomarkers cardiac remodeling risk stratification transthoracic echocardiograph



Subscribe 🔒

 

Abstract

Chronic heart failure with preserved ejection fraction (HFpEF) represents a major public health challenge due to its high prevalence, heterogeneous pathophysiology, and limited opportunities for early diagnosis. Accumulating evidence indicates that HFpEF is preceded by a prolonged subclinical phase characterized by structural and functional myocardial remodeling and chronic low-grade systemic inflammation. This review summarizes current evidence on instrumental and biochemical markers with potential utility for early detection and risk stratification of HFpEF. We highlight the diagnostic value of key echocardiographic parameters, including indices of left-sided cardiac remodeling and myocardial deformation imaging, as sensitive indicators of preclinical myocardial dysfunction. In addition, emerging data on circulating biomarkers of HFpEF are discussed, including natriuretic peptides and markers of inflammation, fibrosis, endothelial dysfunction, and cellulabr stress. Integration of imaging and biochemical parameters into multimarker diagnostic algorithms may facilitate earlier identification of high-risk individuals and improve preventive strategies for HFpEF.

References

  1. Dunlay S.M., Roger V.L., Redfield M.M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 2017; 14 (10): 591–602. DOI: 10.1038/nrcardio.2017.65
  2. Redfield M.M., Borlaug B.A. Heart failure with preserved ejection fraction: a review. JAMA. 2023; 329 (10): 827–838. DOI: 10.1001/jama.2023.2020
  3. Vasan R.S., Enserro D.M., Beiser A.S., Xanthakis V. Lifetime risk of heart failure among participants in the Framingham Study. J. Am. Coll. Cardiol. 2022; 79 (3): 250–263. DOI: 10.1016/j.jacc.2021.10.043
  4. Galyavich A.S., Tereshchenko S.N., Uskach T.M. et al. 2024 Clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology. 2024; 29 (11): 6162 (in Russ.). DOI: 10.15829/1560-4071-2024-6162
  5. Jia X., Al Rifai M., Ndumele C.E. et al. Reclassification of pre-heart failure stages using cardiac biomarkers: the ARIC Study. JACC Heart Fail. 2023; 11 (4): 440–450. DOI: 10.1016/j.jchf.2022.12.005
  6. McDonagh T.A., Metra M., Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021; 42 (36): 3599–3726. DOI: 10.1093/eurheartj/ehab368
  7. Reddy Y.N.V., Carter R.E., Obokata M. et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018; 138 (9): 861–870. DOI: 10.1161/CIRCULATIONAHA.118.034646
  8. Tada A., Nagai T., Omote K. et al. Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: a report from the Japanese multicenter registry. Int. J. Cardiol. 2021; 342: 43–48. DOI: 10.1016/j.ijcard.2021.08.001
  9. Yoon M., Oh J., Lee C.J., Kang S.M. Comparison of the 2021 ESC guideline with the HFA-PEFF and H2FPEF scores in diagnosing heart failure with preserved ejection fraction. Sci. Rep. 2025; 15 (1): 22256. DOI: 10.1038/s41598-025-01537-7
  10. Borlaug B.A. The pathophysiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 2014; 11 (9): 507–515. DOI: 10.1038/nrcardio.2014.83
  11. Yano M., Nishino M., Kawanami S. et al. Impact of structural abnormalities in left ventricle and left atrium on clinical outcomes in heart failure with preserved ejection fraction. Int. Heart J. 2023; 64 (5): 875–884. DOI: 10.1536/ihj.23-277
  12. Matskeplishvili S.T., Saidova M.A., Mironenko M.Yu. et al. Standard transthoracic echocardiography. Guidelines 2024. Russian Journal of Cardiology. 2025; 30 (2): 6271 (in Russ.). DOI: 10.15829/1560-4071-2025-6271
  13. Haass M., Kitzman D.W., Anand I.S. et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ. Heart Fail. 2011; 4 (3): 324–331. DOI: 10.1161/CIRCHEARTFAILURE.110.959890
  14. Dzhioeva O.N., Maksimov O.A., Rogozhkina E.A., Drapkina O.M. Aspects of transthoracic echocardiography protocol in obese patients. Russian Journal of Cardiology. 2022; 27 (12): 5243 (in Russ.). DOI: 10.15829/1560-4071-2022-5243
  15. Tromp J., MacDonald M.R., Tay W.T. et al. Heart failure with preserved ejection fraction in the young. Circulation. 2018; 138 (24): 2763–2773. DOI: 10.1161/CIRCULATIONAHA.118.034720
  16. Hao Z., Xu G., Yuan M. et al. The predictive value of changes in left atrial volume index for rehospitalization in heart failure with preserved ejection fraction. Clin. Cardiol. 2023; 46 (2): 151–158. DOI: 10.1002/clc.23952
  17. Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2015; 28 (1): 1–39.e14. DOI: 10.1016/j.echo.2014.10.003
  18. Nassri Camara E.J., do Prado Valladares F.R., Key N.K. et al. Indexing of left atrial volume by body surface area and height in a Brazilian population without previous heart disease and with a normal heart on echocardiography. Behavior in obese and overweight patients. Cardiol. Cardiovasc. Med. 2023; 7 (1): 25–31. DOI: 10.26502/fccm.92920304
  19. Lim D.J., Varadarajan V., Quinaglia T. et al. Change in left atrial function and volume predicts incident heart failure with preserved and reduced ejection fraction: multi-ethnic study of atherosclerosis. Eur. Heart J. Cardiovasc. Imaging. 2024; 25 (11): 1577–1587. DOI: 10.1093/ehjci/jeae138
  20. Wang N., Rueter P., Ng M. et al. Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction. Eur. J. Heart Fail. 2024; 26 (8): 1778–1787. DOI: 10.1002/ejhf.3271
  21. Nagueh S.F., Smiseth O.A., Appleton C.P. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2016; 29 (4): 277–314. DOI: 10.1016/j.echo.2016.01.011
  22. Ivanova A.A., Rogozhkina E.A., Timofeev Yu.S. et al. Markers of heart failure with preserved ejection fraction in patients with unexplained dyspnea. Cardiovascular Therapy and Prevention. 2023; 22 (10): 3769 (in Russ.). DOI: 10.15829/1728-8800-2023-3769
  23. D’Andrea A., Vriz O., Ferrara F. et al. Reference ranges and physiologic variations of left E/e’ ratio in healthy adults: clinical and echocardiographic correlates. J. Cardiovasc. Echogr. 2018; 28 (2): 101–108. DOI: 10.4103/jcecho.jcecho_57_17
  24. Nauta J.F., Hummel Y.M., van der Meer P. et al. Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. Eur. J. Heart Fail. 2018; 20 (9): 1303–1311. DOI: 10.1002/ejhf.1220
  25. Robinson S., Ring L., Oxborough D. et al. The assessment of left ventricular diastolic function: guidance and recommendations from the British Society of Echocardiography. Echo Res. Pract. 2024; 11 (1): 16. DOI: 10.1186/s44156-024-00051-2
  26. Haji K., Huynh Q., Wong C. et al. Improving the characterization of stage A and B heart failure by adding global longitudinal strain. JACC Cardiovasc. Imaging. 2022; 15 (8): 1380–1387. DOI: 10.1016/j.jcmg.2022.03.007
  27. Cho D.H., Park S.M. Epicardial adipose tissue and heart failure, friend or foe? Diabetes Metab. J. 2024; 48 (3): 373–384. DOI: 10.4093/dmj.2023.0190
  28. Mahabadi A.A., Anapliotis V., Dykun I. et al. Epicardial fat and incident heart failure with preserved ejection fraction in patients with coronary artery disease. Int. J. Cardiol. 2022; 357: 140–145. DOI: 10.1016/j.ijcard.2022.04.009
  29. van Woerden G., Gorter T.M., Westenbrink B.D. et al. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. Eur. J. Heart Fail. 2018; 20 (11): 1559–1566. DOI: 10.1002/ejhf.1283
  30. Sozzi F.B., Maganti K., Malanchini G. et al. Diastolic stress test in heart failure with preserved ejection fraction. Eur. J. Prev. Cardiol. 2020; 27 (19): 2089–2091. DOI: 10.1177/2047487319858796
  31. Obokata M., Kane G.C., Reddy Y.N. et al. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation. 2017; 135 (9): 825–838. DOI: 10.1161/CIRCULATIONAHA.116.024822
  32. Massa L., Baratto C., Perego G.B. et al. The added value of cardiopulmonary exercise testing in the diagnosis of heart failure with preserved ejection fraction. Eur. Heart J. 2024; 45: ehae666.957. DOI: 10.1093/eurheartj/ehae666.957
  33. Pugliese N.R., De Biase N., Gargani L. et al. Predicting the transition to and progression of heart failure with preserved ejection fraction: a weighted risk score using bio-humoural, cardiopulmonary, and echocardiographic stress testing. Eur. J. Prev. Cardiol. 2021; 28 (15): 1650–1661. DOI: 10.1093/eurjpc/zwaa129
  34. Podzolkov V.I., Dragomiretskaya N.A., Beliaev I.G. et al. Galectin-3 as a marker of cardiorenal syndrome in patients with chronic heart failure. Rational Pharmacotherapy in Cardiology. 2022; 18 (2): 153–159 (in Russ.). DOI: 10.20996/1819-6446-2022-04-04
  35. Filatova A.Yu., Sobolevskaya M.S., Potekhina A.V. et al. Prognostic value of soluble biomarkers of haemodynamic stress, inflammation and fibrosis in HFpEF: a retrospective cohort study. Russian Cardiology Bulletin. 2024; 19 (2): 47–54 (in Russ.). DOI: 10.17116/Cardiobulletin20241902147
  36. Lebedev D.A., Lyasnikova E.A., Vasilyeva A.A. et al. Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes. Russian Journal of Cardiology. 2020; 25 (10): 3967 (in Russ.). DOI: 10.15829/1560-4071-2020-3967
  37. Kopeva K.V., Mochula A.V., Maltseva A.N. et al. Heart failure with preserved ejection fraction: the role of microvascular dysfunction. Bulletin of Siberian Medicine. 2022; 21 (4): 88–97 (in Russ.). DOI: 10.20538/1682-0363-2022-4-88-97
  38. Zhbanov K.A., Salakheeva E.Yu., Sokolova I.Ya. et al. Neuregulin-1β, biomarkers of inflammation and myocardial fibrosis in heart failure patients. Rational Pharmacotherapy in Cardiology. 2022; 18 (5): 522–529 (in Russ.). DOI: 10.20996/1819-6446-2022-09-05
  39. Vitt K.N., Kuzheleva E.A., Tukish O.V. et al. Low-intensity inflammation as a manifestation of comorbidity and a factor in the unfavorable clinical course of heart failure with preserved ejection fraction. Cardiovascular Therapy and Prevention. 2024; 23 (2): 3847 (in Russ.). DOI: 10.15829/1728-8800-2024-3847
  40. Timofeev Yu.S., Fokina Yu.A., Metelskaya V.A. et al. Associations of cartilage intermediate layer protein 1 and hypoxia-inducible factor-1-alpha with transthoracic echocardiography results in patients with heart failure with preserved ejection fraction. Russian Journal of Cardiology. 2024; 29 (6): 5908 (in Russ.). DOI: 10.15829/1560-4071-2024-5908
  41. Kopeva K.V., Maltseva A.N., Mochula A.V. et al. The role of markers of endothelial dysfunction in the pathogenesis of coronary microvascular dysfunction in patients with non-obstructive coronary artery disease. Bulletin of Siberian Medicine. 2024; 23 (3): 49–58 (in Russ.). DOI: 10.20538/1682-0363-2024-3-49-58
  42. Timofeev Yu.S., Afaunova A.R., Ivanova A.A. et al. Interaction of serum heat shock proteins’ levels with the severity of venous congestion in patients with acute decompensated heart failure with preserved ejection fraction. Cardiovascular Therapy and Prevention. 2024; 23 (6): 4037 (in Russ.). DOI: 10.15829/1728-8800-2024-4037
  43. Watson C.J., Gallagher J., Wilkinson M. et al. Biomarker profiling for risk of future heart failure (HFpEF) development. J. Transl. Med. 2021; 19 (1): 61. DOI: 10.1186/s12967-021-02735-3
  44. Pandey A., Vaduganathan M., Patel K.V. et al. Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. JACC Heart Fail. 2021; 9 (3): 215–223. DOI: 10.1016/j.jchf.2020.10.013

About Authors

  • Olga N. Dzhioeva, Dr. Med. Sci., Leading Researcher, Head of Laboratory; ORCID
  • Anna A. Ivanova, Cand. Med. Sci., Junior Researcher; ORCID
  • Elizaveta A. Rogozhkina, Cand. Med. Sci., Junior Researcher; ORCID
  • Yuriy S. Timofeev, Cand. Med. Sci., Senior Researcher, Head of Department; ORCID
  • Oksana M. Drapkina, Dr. Med. Sci., Professor, Academician of RAS, Director; ORCID

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by